Latest Close
$132.63
Stock Hub
ABVX
Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$126.61 (+2103.16%)
Market Cap
$10.57B
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$5.69 to $148.83
Target Mean Price
$155.20
Beta
-0.19
Trailing P/E
Not available
Forward P/E
-52.20
Price / Book
21.04
Company Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.